Acomplia - Rimonabant
Acomplia active ingredient is Rimonabant.
Acomplia (Rimonabant) is a new diet drug that shows huge promise
for treating obesity, as well as treating related disorders.
Acomplia developed by Sanofi-Aventis.
You may also see it referred to as "Zimulti," another
trademarked name apparently being considered by Sanofi-Aventis
for the marketing of rimonabant. It could also be referred to
as "Accomplia"...
The only certain name is its chemical name, Rimonabant.
What is Acomplia Rimonabant?
Acomplia (Rimonabant) is a "selective CB1 endocannabinoid
receptor antagonist". In layperson's language, this means
that acomplia rimonabant blocks the body's natural cellular response
to certain events, including the intake of food.
How Acomplia Rimonabant works?
Acomplia (Rimonabant) works by exploiting a newly discovered
system in the body. This system is believed to regulate food intake
and energy expenditure in the human body. It blocks a receptor
that exists on certain cells in the human body, including cells
related to weight gain. When the receptor is blocked, human appetite
for food is reduced. Acomplia has also been shown to improve HDL
(good cholesterol) and triglyceride levels, showing benefit for
diabetes and heart conditions.
Acomplia Rimonabant dosage
The most beneficial doses of Acomplia (Rimonabant) noted in the
trials have been 20 mg daily.
|
We
compare buying conditions of all respectable suppliers that
offer Rimonabant online
News
and Articles:
